Skip to main content
Evidence Snapshot

RT-112

CHEMBL614145 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:48:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614145
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RT-112 as ChEMBL target CHEMBL614145. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
RT-112
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614145
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why RT-112 matters

As of 2026-09-13

RT-112 is reviewed as RT-112; the current evidence base includes 33 approved drugs, 268 compounds, and 89 assays, with lead potency reaching pChEMBL 9.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 33 approved drugs, 268 compounds, and 89 assays for this target. The dominant activity type is IC50. CHEMBL888 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL888 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
33 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why RT-112 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

268
Total Compounds
89
Total Assays
33
Approved Drugs
IC50: 291.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
9.9 IC50 Approved
No preferred name
CHEMBL3348846
9.2 IC50 Clinical
9.2 IC50 Clinical
No preferred name
CHEMBL3545252
8.9 IC50 Approved
No preferred name
CHEMBL3545376
8.9 IC50 Approved

Approved Drugs

Structure Compound First Approval
FUTIBATINIB
CHEMBL3701238
2022
2021
INFIGRATINIB
CHEMBL1852688
2021
PEMIGATINIB
CHEMBL4297522
2020
ERDAFITINIB
CHEMBL3545376
2019
MIDOSTAURIN
CHEMBL608533
2017
PALBOCICLIB
CHEMBL189963
2015
PONATINIB
CHEMBL1171837
2012
TEMSIROLIMUS
CHEMBL1201182
2007
GEMCITABINE
CHEMBL888
1996
DOCETAXEL
CHEMBL3545252
1995
VINORELBINE
CHEMBL553025
1994
PACLITAXEL
CHEMBL428647
1992
ETOPOSIDE
CHEMBL44657
1983
MITOMYCIN
CHEMBL105
1981
DOXORUBICIN
CHEMBL53463
1974
CYTARABINE
CHEMBL803
1969
VINBLASTINE
CHEMBL159
1965
METHOTREXATE
CHEMBL34259
1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:48:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614145